U.S. E-cigarette Regulation Sought By Health Care Stakeholders, Industry
This article was originally published in The Tan Sheet
The U.K. move to regulate all electronic cigarettes as medical products could help build the case for U.S. regulation by fostering research, experts say. Some e-cigarette firms are anxious for FDA to regulate the products, but also are concerned about the potential impact of CTP oversight.
You may also be interested in...
The U.K. pharma regulator requires all electronic cigarettes to be licensed as nonprescription medicines beginning in 2016, noting concerns about product quality. Meanwhile, FDA considers allowing e-cigarettes to be marketed as nicotine replacement therapy on a case-by-case basis.
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.